文献速递淋巴瘤

来那度胺联合利妥昔单抗免疫治疗通过互补作用机制激活抗肿瘤免疫并诱导滤泡性淋巴瘤肿瘤细胞死亡

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
PubMed 文献 · Br J Haematol · 2019-02-14

该研究通过体外实验和3期试验患者样本分析,探讨来那度胺联合利妥昔单抗(R2)在滤泡性淋巴瘤中的免疫调节机制。结果显示R2可增强T细胞和NK细胞功能、改善抗体依赖细胞毒性,并增加循环T/NK细胞计数,同时来那度胺引起可逆的中性粒细胞成熟停滞,可能解释R2较R-化疗中性粒细胞减少发生率更低。

要点

  • 来那度胺体外可逆转滤泡性淋巴瘤患者功能失调的T细胞和NK细胞,增强增殖能力及Th1细胞因子释放。
  • R2通过cereblon依赖机制改善对敏感及化疗耐药FL细胞的抗体依赖细胞毒性,联合优于单药。
  • 3期试验患者样本显示R2增加循环T/NK细胞计数,而R-化疗降低细胞数量。

核心结论

  • 作者认为这些数据支持滤泡性淋巴瘤治疗范式转变,从联合免疫化疗转向无化疗免疫治疗。

研究设计与样本

  • 体外实验结合3期试验滤泡性淋巴瘤患者样本的免疫表型分析,以及髓系分化体外模型。

主要发现

  • 来那度胺可逆转滤泡性淋巴瘤患者功能失调的T细胞和NK细胞,增强增殖能力及Th1细胞因子释放。
  • 与利妥昔单抗联合时,来那度胺通过cereblon依赖机制改善对敏感和化疗耐药滤泡性淋巴瘤细胞的抗体依赖细胞毒性。
  • 单药来那度胺和利妥昔单抗均增加裂解性NK细胞与原发性滤泡性淋巴瘤肿瘤细胞形成免疫突触,联合方案更优并与细胞毒性增强相关。
  • 3期试验患者样本免疫表型显示,R2治疗增加循环T细胞和NK细胞计数,而R-化疗与细胞数量减少相关。
  • 体外髓系分化模型中,来那度胺引起可逆的中性粒细胞成熟停滞,不同于细胞毒性化疗药物,可能有助于解释R2较R-化疗中性粒细胞减少发生率更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R2 ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. In combination with rituximab, lenalidomide improved antibody-dependent cellular cytotoxicity in sensitive and chemo-resistant FL cells, via a cereblon-dependent mechanism. While single-agent lenalidomide and rituximab increased formation of lytic NK cell immunological synapses with primary FL tumour cells, the combination was superior and correlated with enhanced cytotoxicity. Immunophenotyping of FL patient samples from a phase 3 trial revealed that R2 treatment increased circulating T- and NK-cell counts, while R-chemotherapy was associated with reduced cell numbers. Finally, using an in vitro model of myeloid differentiation, we demonstrated that lenalidomide caused a reversible arrest in neutrophil maturation that was distinct from a cytotoxic chemotherapeutic agent, which may help explain the lower rates of neutropenia observed with R2 versus R-chemotherapy. Taken together, we believe these data support a paradigm shift in the treatment of FL - moving from combination immunochemotherapy to chemotherapy-free immunotherapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chiu H, Trisal P, Bjorklund C, et al. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019. PMID: 30767211. doi:10.1111/bjh.15797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。